ClinicalTrials.gg
RecruitingNCT07672769BEXERAUpdated Nov 13, 2026

Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes

A Phase 2 interventional study of bexmarilimab (1mg/kg) and azacitidine in Higher Risk Myelodysplastic Syndromes, sponsored by Faron Pharmaceuticals Ltd. Recruiting at 35 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Faron Pharmaceuticals Ltd · Phase 2, Interventional, and Treatment

Updated Nov 13, 2026Now RecruitingFirst sites in 7 new countries+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This Phase IIb study (BEXERA) will evaluate the safety and efficacy of bexmarilimab (FP-1305), an antibody targeting Clever-1, given in combination with azacitidine compared with azacitidine plus placebo in adults with treatment-naïve higher-risk myelodysplastic syndromes (HR-MDS). Participants will be randomized to receive bexmarilimab at one of two dose levels (1 mg/kg or 3 mg/kg) plus azacitidine, or placebo plus azacitidine. The primary aim is to select the recommended dose of bexmarilimab for subsequent development based on a predefined integration of clinical response and safety/tolerability.

02

Conditions studied

  • Higher Risk Myelodysplastic Syndromes

Browse trials for

Keywords

  • higher risk myelodysplastic syndromes
  • HR-MDS
  • Bexmarilimab
  • Hematoligical
  • Malignancies
  • Immunotherapy
  • CLEVER-1
  • anti-CLEVER-1
  • MDS
  • azacitidine
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 90 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Faron Pharmaceuticals Ltd is the lead sponsor of 8 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant provides written .
  2. Participant is ≥18 years of age.
  3. Participant has newly diagnosed MDS with morphologically confirmed HR-MDS as defined according to 2022 World Health Organization classification (5th Edition, Annex 7).

    1. IPSS-M classification of moderately high risk, high risk, and very high risk.
    2. \<20% bone marrow blasts per bone marrow /aspirate at screening
  4. Participant is eligible for azacitidine per local practice and willing to initiate trial therapy.
  5. Participant has performance score 0 to 2.
  6. Participant has ≥3 months.
  7. Participant has adequate organ function: ≥30 mL/min (Cockcroft-Gault); indirect (unconjugated) ≤1.5 times the (ULN) (unless related to Gilbert's syndrome, in which case the indirect bilirubin levels must be \<3×ULN for inclusion); (AST) or alanine aminotransferase (ALT) ≤3×ULN.
  8. Participant has baseline leukocyte count of \<20×109/L. Hydroxycarbamide use is permitted to meet this criterion.
  9. Women of have a negative pregnancy test; participants of childbearing potential (and their partners) agree to use highly effective during treatment and for ≥6 months after last dose.
  10. Participant is willing and able to comply with protocol procedures and follow up.

Exclusion criteria

Exclusion Criteria:

  1. Participant has a previous diagnosis of AML, has transformed to AML, or has MDS subtypes outside the scope or overlapping myeloid neoplasms: MDS evolved from pre-existing myeloproliferative neoplasms (MPN); MDS/MPN overlap (e.g., chronic myelomonocytic leukemia, acute chronic myeloid leukemia, juvenile myelomonocytic leukemia, unclassifiable); advanced myelofibrosis (MF Grade ≥3); or severe hemolysis.
  2. Participants who are considered appropriate candidates for immediate haematopoietic stem cell transplantation (HSCT) at the time of screening are excluded, irrespective of transplant timing, donor availability, or planned bridging therapy. Determination of transplant candidacy should be based on institutional standards and routine clinical practice, including assessment of individual clinical factors such as age, performance status, comorbidities, organ function, disease risk, and donor suitability.
  3. Participants with ≥20% blasts in peripheral blood or bone marrow or evidence of myeloid sarcoma (extramedullary AML).
  4. Participant has a lack of screening cytogenetic data or demonstrated normal karyotype per local or central analysis, should the patient have \<5% blasts at screening.
  5. Participant has received previous lines of anticancer therapy for MDS (disease-modifying therapy), including HMAs (e.g., azacitidine, decitabine), chemotherapy, or HSCT. Supportive care (e.g., transfusions, growth factors) is permitted.
  6. Participant has cardiac disease: recent myocardial infarction within 12 months; symptomatic congestive heart failure ( Class III or IV) or (LVEF) \<40%; uncontrolled clinically significant arrhythmias; or congenital/familial long- syndrome or pre-excitation syndrome.
  7. Participant has active, uncontrolled infection requiring IV antimicrobials; known active invasive fungal infection; uncontrolled severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection per local standards.
  8. Participant has known active central nervous system (CNS) involvement by myeloid
  9. All prior allo-HSCT within 6 months before Screening; ongoing clinically significant (GVHD) requiring systemic .
  10. Participant has active autoimmune disease requiring systemic therapy or requiring ≥10 mg/day prednisone (or equivalent) within 14 days prior to first dose; topical/inhaled/ophthalmic permitted. (Immune conditions such as type 1 diabetes, controlled thyroid disease, vitiligo, psoriasis, alopecia are not exclusions.)
  11. Participant has clinically relevant hepatic disease (e.g., C) or /AST >3× and exceeding inclusion thresholds (indirect [unconjugated] bilirubin >1.5×ULN [unless related to Gilbert's syndrome, in which case the indirect bilirubin levels must be >3×ULN]); persistent chronic ulcers with high risk of infection per investigator's assessment.
  12. Participant has received recent non-MDS related anticancer therapy or agents within drug-specified (e.g., \<21 days from last IV/SC cytotoxic, \<14 days or \<5 half-lives for small-molecule therapy, \<4 weeks for other immunotherapies).
  13. Participant has a history of another malignancy that is active, progressing, or has required systemic treatment within the past 2 years of screening, excluding non-melanoma skin cancer, carcinoma in situ treated with curative intent.
  14. Participant has known uncontrolled , active virus, or virus with high-level viremia; participants with controlled viral infections on stable therapy may be eligible per local guidance.
  15. Participant is pregnant or lactating.
  16. Participant has prior exposure to bexmarilimab.
  17. Participant has any condition, including psychiatric or substance-use disorder, that in the investigator's judgment would compromise , compliance, or interpretation of trial results.
  18. Participant has a history of to compounds related to immunotherapy or to any of their .
  19. Participant has undergone major surgery within 4 weeks of Cycle 1 Day 1.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Bexmarilimab (1mg/kg) and azacitidine

    Standard of care azacitidine as per label/institutional practice; Bexmarilimab weekly (Q1W), Intravenous.

    Drug: bexmarilimab (1mg/kg) · Drug: azacitidine

  • Experimental
    Bexmarilimab (3mg/kg) and azacitidine

    Standard of care azacitidine as per label/institutional practice; Bexmarilimab weekly (Q1W), Intravenous.

    Drug: azacitidine · Drug: bexmarilimab (3mg/kg)

  • Placebo comparator
    Placebo and azacitidine

    Standard of care azacitidine as per label/institutional practice; Placebo weekly (Q1W), Intravenous.

    Drug: azacitidine · Drug: Placebo

Interventions

  • Drugbexmarilimab (1mg/kg)

    Drug page: Bexmarilimab

    1mg/kg. Administered weekly (Q1W) with the opportunity to reduce frequency to biweekly (Q2W) based on time on treatment and disease response. Intravenous (IV) administration

    Also known as: FP-1305

  • Standard of care medication, administered per institutional guidelines/label

  • DrugPlacebo

    Participants will receive saline placebo, prepared by the local site pharmacy to match bexmarilimab at point of dispensation. Administered on a schedule to match bexmarilimab

  • Drugbexmarilimab (3mg/kg)

    Drug page: Bexmarilimab

    3mg/kg. Administered weekly (Q1W) with the opportunity to reduce frequency to biweekly (Q2W) based on time on treatment and disease response. Intravenous (IV) administration

    Also known as: FP-1305

06

What researchers measure

Primary outcomes

  1. Dose selection utility score utilising efficacy and safety components.

    Dose-selection utility formula at the end of the primary dose-selection assessment window, calculated per dose using a pre-specified algorithm that integrates: * Efficacy component (achievement of CR + CReq per International Working Group \[IWG\] 2023 criteria). * Safety/tolerability component (rate of treatment-emergent Grade 3-5 adverse events or rate of treatment-related Grade 3-5 adverse events). For each arm, there will be an observed efficacy rate (PE) and toxicity rate (PT) and the utility calculation will be defined as U = PE - ωPT where the ω is a pre-specified weight.

    Time frame: 3-4 months from last participant enrollment

Secondary outcomes

  1. Complete Remission (CR) and Complete Remission Equivalent (CReq)

    Proportion of responses meeting CR or CReq based on IWG 2023 criteria. Endpoints of best response 3-months on treatment, 6-months on treatments and through full treatment period.

    Time frame: 36 months from enrollment

  2. Composite Complete Remission (cCR) defined by IWG2023

    cCR as defined by the IWG2023 at any point through participant treatment

    Time frame: 36 months from enrollment

  3. Overall Response Rate (ORR)

    ORR as defined by IWG2006 response criteria and IWG2023 criteria

    Time frame: 36 months from enrollment

  4. Overall Survival (OS)

    OS is defined as the number of months measured from the date of enrollment to the date of death from any cause.

    Time frame: 36 months from enrollment

  5. Event Free Survival (EFS)

    EFS will be defined as the number of days from the date of enrollment to the date of earliest evidence of disease progression, transformation to AML, or death from any cause

    Time frame: 36 months from enrollment

  6. Complete Remission (CR) defined by IWG2006

    CR as defined by the IWG2006 at any point through participant treatment

    Time frame: 36 months from enrollment

  7. Reporting of frequency and severity of adverse events (AEs), serious adverse events (SAE) and laboratory abnormalities

    Reporting of the number of participants and severity of AEs, SAEs and laboratory abnormalities using NCI-CTCAE v5.0 grading

    Time frame: 36 months from enrollment

  8. Time to response

    Time to response will be defined as the number of days from the date of enrollment to the first treatment response.

    Time frame: 36 months from enrollment

  9. Duration of Response (DOR)

    DOR will be defined as the number of days from the date of first documented response to the earliest evidence of relapse or death.

    Time frame: 36 months from enrollment

  10. Percentage of Participants Achieving Transfusion Independence (TI) Who are Transfusion Dependent (TD) at Baseline

    TD at baseline is defined as receipt of three or more RBC units or platelet transfusions within ≥56 days prior to the start of study treatment. TI is defined as the absence of RBC and platelet transfusions for ≥56 days in an observation period of 8-24 weeks with the same transfusion policy compared to within 8 weeks prior to treatment.

    Time frame: 36 months from enrollment

  11. Time to transformation to AML

    The time to transformation to AML is defined as the number of days from the date of enrollment until the date of documented AML transformation, defined as a bone marrow blast count ≥20% independent of baseline bone marrow count. Patients who do not transform to AML are censored at the date of last follow-up or date of death.

    Time frame: 36 months from enrollment

  12. Rate of Allogeneic hematopoietic stem cell transplantation (allo-HSCT)

    The rate of allogeneic HSCT will be assessed as the proportion of participants who proceed to transplant after enrollment.

    Time frame: 36 months from enrollment

  13. Number of infections and hospitalizations

    Frequency of infections and participant hospitalization

    Time frame: 36 months from enrollment

  14. To characterize the pharmacokinetic (PK) profile of bexmarilimab plus azacitidine at two bexmarilimab doses

    Bexmarilimab concentration in serum and PK parameters

    Time frame: 36 months from enrollment

  15. To characterize the immunogenicity profile of bexmarilimab plus azacitidine at two bexmarilimab doses

    Anti-bexmarilimab antibody detection levels across different treatment arms

    Time frame: 36 months from enrollment

  16. To characterize the pharmacodynamic (PD) profile of bexmarilimab plus azacitidine at two bexmarilimab doses

    Free soluble Clever-1 (PD marker) detection in bone marrow and blood. Levels compared against different treatment arms

    Time frame: 36 months from enrollment

Other outcomes

  1. Minimal Residual Disease (MRD)-Negative Response Rate

    The MRD-negative response rate is defined as the percentage of participants who achieved a CR or CReq based on Investigator-assessed IWG criteria and reached MRD-negative disease status prior to initiation of any new anticancer therapy, including HSCT.

    Time frame: 36 months from enrollment

07

Study locations

4 of 35 sites recruiting
  • City of Hope Medical Center
    Duarte, California 91010, United States
    Recruiting
    • Carlos Hernandez · Contactcarloshernandez@coh.org · 626-218-0867
    • Anthony S Stein, MD · Principal investigator
  • University of Colorado Cancer Center
    Aurora, Colorado 80045, United States
    Not yet recruiting
  • Yale Cancer Center
    New Haven, Connecticut 06510, United States
    Not yet recruiting
    • Ria Syam · Contactria.syam@yale.edu · 203-737-7103
    • Amer M Zeidan, MBBS, MD · Principal investigator
  • Moffitt Malignant Hematology & Cellular Therapy at Memorial Healthcare System
    Pembroke Pines, Florida 33028, United States
    Not yet recruiting
    • Anna Chockley · ContactAChockley@mhs.net · 954-276-9352
    • Jonathan A Feld, MD · Principal investigator
  • Mass General Brigham Cancer Institute
    Boston, Massachusetts 02114, United States
    Not yet recruiting
  • University of North Carolina Lineberger Comprehensive Cancer Center
    Chapel Hill, North Carolina 27599, United States
    Not yet recruiting
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
    Not yet recruiting
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
    Not yet recruiting
    • Maggie N Thompson, MD · ContactMNThompson1@mdanderson.org · 832-247-4334
    • Guillermo Garcia-Manero, MD · Principal investigator
  • Medical College of Wisconsin - Clinical Cancer Center - Froedtert Hospital
    Milwaukee, Wisconsin 53226, United States
    Not yet recruiting
    • Deepa Pereira · Contactdpereira@mcw.edu · 414-805-0505
    • Guru S Murthy, MD · Principal investigator
  • Fakultní nemocnice Brno
    Brno, 625 00, Czechia
    Not yet recruiting
    • Libor Cervinek · Principal investigator
  • Fakultní nemocnice Hradec Králové
    Hradec Králové, 500 05, Czechia
    Not yet recruiting
    • Petra Belohlavkova · Principal investigator
  • Fakultni nemocnice Ostrava
    Ostrava-Poruba, 708 52, Czechia
    Not yet recruiting
    • Zdenek Koristek · Principal investigator
  • Ustav hematologie a krevni transfuze
    Prague, 128 00, Czechia
    Not yet recruiting
    • Marketa Markova · Principal investigator
  • Vseobecna fakultni nemocnice v Praze
    Prague, 128 08, Czechia
    Not yet recruiting
    • Anna Jonasova · Principal investigator
  • Helsinki University Hospital Comprehensive Cancer Center
    Helsinki, 00290, Finland
    Not yet recruiting
    • Mika Kontro, MDS · Principal investigator
  • Oulu University Hospital
    Oulu, 90029, Finland
    Not yet recruiting
    • Kirsi Launonen · Principal investigator
  • Tampere University Hospital
    Tampere, 33520, Finland
    Not yet recruiting
    • Johanna Rimpilainen, MD · Principal investigator
  • Turku University Hospital
    Turku, 20520, Finland
    Not yet recruiting
    • Pia-Sofia Ettala · Principal investigator
  • CHU de Bordeaux
    Bordeaux, 33000, France
    Not yet recruiting
    • Sophie Dimicoli-Salazar · Principal investigator
  • Hôpital Saint-Louis
    Paris, 75010, France
    Not yet recruiting
    • Lionel Ades · Principal investigator
  • CHU de Poitiers
    Poitiers, 86000, France
    Not yet recruiting
    • Jose Torregrosa Diaz · Principal investigator
  • The Institut Gustave Roussy
    Villejuif, 94805, France
    Not yet recruiting
    • Christophe Willekens · Principal investigator
  • AOU SS. Antonio e Biagio e Cesare Arrigo
    Alessandria, 15121, Italy
    Not yet recruiting
    • Monia Marchetti · Principal investigator
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna
    Bologna, 40138, Italy
    Not yet recruiting
    • Antonio Curti · Principal investigator
  • INOC - Istituto Nazionale Oncologico Candiolo
    Candiolo, 10060, Italy
    Not yet recruiting
    • Elena Crisa · Principal investigator
  • IRCCS Istituto Europeo di Oncologia
    Milan, 20141, Italy
    Not yet recruiting
    • Enrico Derenzini · Principal investigator
  • Pratia Onkologia Katowice
    Katowice, 40-519, Poland
    Not yet recruiting
    • Sebastian Grosicki · Principal investigator
  • Aidport Clinical Trials Hospital
    Skórzewo, 60-185, Poland
    Not yet recruiting
    • Maciej Kazmierczak · Principal investigator
  • MTZ Clinical Research Powered by Pratia
    Warsaw, 02-172, Poland
    Not yet recruiting
    • Krzysztof Madry · Principal investigator
  • King's College Hospital
    London, Greater London SE59RS, United Kingdom
    Recruiting
    • Austin G Kulasekararaj, MBBS, MD · Principal investigator
    • Henry Wood · Sub investigator
    • Jennifer Vidler · Sub investigator
    • Roochi Trikha · Sub investigator
  • The Christie NHS Foundation Trust
    Manchester, Greater Manchester M204BX, United Kingdom
    Recruiting
    • The Christie Haematology and Transplant Research Team · Contactthe-christie.HaematologyClinicTrl@nhs.net
    • Tim Summervaille · Sub investigator
    • Mike Dennis · Sub investigator
    • Justin Loke · Principal investigator
    • John Chadwick · Sub investigator
    • Daniel Wiseman · Sub investigator
  • Maidstone and Tunbridge Wells NHS Trust
    Maidstone, Kent ME169QQ, United Kingdom
    Not yet recruiting
    • Evangelia Dimitriadou · Principal investigator
    • Lalita Banerjee · Sub investigator
  • University Hospital Birmingham Nhs Trust
    Birmingham, B152GW, United Kingdom
    Not yet recruiting
    • Manoj Raghavan · Principal investigator
  • The Beatson West of Scotland Cancer Centre
    Glasgow, G120XH, United Kingdom
    Not yet recruiting
    • Gillian Horne · Principal investigator
  • Royal Cornwall Hospitals NHS Trust
    Truro, TR13LJ, United Kingdom
    Recruiting
    • Denise Storey · Contactdenisestorey@nhs.net · +441872253075
    • Ruth Witherall, MD · Principal investigator
    • Cristina Thiebaud, MD · Sub investigator
08

References and documents

Publications

  • Kontro M, Stein AS, Pyorala M, Rimpilainen J, Siitonen T, Ylitalo A, Fjallskog ML, Jalkanen J, Aakko S, Pawlitzky I, Hollmen M, Daver N. Bexmarilimab plus azacitidine for high-risk myelodysplastic syndrome and relapsed or refractory acute myeloid leukaemia: results from the dose-escalation part of a multicentre, single-arm, phase 1/2 trial. Lancet Haematol. 2025 Jul;12(7):e516-e528. doi: 10.1016/S2352-3026(25)00103-6. Epub 2025 May 28. PubMed 40449509 ↗

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2027, 12 months later.

Of 179 industry-sponsored phase 2 interventional studies under Neoplasms, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 68. This study's planned 12 months is below that.

Counting every sponsor, half of 514 studies reached it within 52 months; a quarter within 33 and three quarters within 92.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Nov 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2026
First posted
Jun 29, 2026
StartEst.
Nov 2026was Oct 2026
Primary completionEst.
Nov 2027
CompletionEst.
Dec 2030
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 20, 2026
Sites
35 sites added — first sites in Czechia, Finland, France, Italy, Poland and 2 more
All 7 countries

Czechia, Finland, France, Italy, Poland, United Kingdom, United States

. 3 sites changed recruiting status (3 now recruiting)
Show 3 sites
  • City of Hope Medical Center · Duarte, United StatesNot yet recruiting→Recruiting
  • The Christie NHS Foundation Trust · Manchester, United KingdomNot yet recruiting→Recruiting
  • Royal Cornwall Hospitals NHS Trust · Truro, United KingdomNot yet recruiting→Recruiting
Show 35 added (9 United States, 6 United Kingdom, 5 Czechia, 4 Finland, 4 France, 4 Italy, 3 Poland)
  • City of Hope Medical Center · Duarte, United States
  • University of Colorado Cancer Center · Aurora, United States
  • Yale Cancer Center · New Haven, United States
  • Moffitt Malignant Hematology & Cellular Therapy at Memorial Healthcare System · Pembroke Pines, United States
  • Mass General Brigham Cancer Institute · Boston, United States
  • University of North Carolina Lineberger Comprehensive Cancer Center · Chapel Hill, United States
  • Vanderbilt University Medical Center · Nashville, United States
  • The University of Texas MD Anderson Cancer Center · Houston, United States
  • Medical College of Wisconsin - Clinical Cancer Center - Froedtert Hospital · Milwaukee, United States
  • Fakultní nemocnice Brno · Brno, Czechia
  • Fakultní nemocnice Hradec Králové · Hradec Králové, Czechia
  • Fakultni nemocnice Ostrava · Ostrava-Poruba, Czechia
  • Ustav hematologie a krevni transfuze · Prague, Czechia
  • Vseobecna fakultni nemocnice v Praze · Prague, Czechia
  • Helsinki University Hospital Comprehensive Cancer Center · Helsinki, Finland
  • Oulu University Hospital · Oulu, Finland
  • Tampere University Hospital · Tampere, Finland
  • Turku University Hospital · Turku, Finland
  • CHU de Bordeaux · Bordeaux, France
  • Hôpital Saint-Louis · Paris, France
  • CHU de Poitiers · Poitiers, France
  • The Institut Gustave Roussy · Villejuif, France
  • AOU SS. Antonio e Biagio e Cesare Arrigo · Alessandria, Italy
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, Italy
  • INOC - Istituto Nazionale Oncologico Candiolo · Candiolo, Italy
  • IRCCS Istituto Europeo di Oncologia · Milan, Italy
  • Pratia Onkologia Katowice · Katowice, Poland
  • Aidport Clinical Trials Hospital · Skórzewo, Poland
  • MTZ Clinical Research Powered by Pratia · Warsaw, Poland
  • King's College Hospital · London, United Kingdom
  • …and 5 more on the registry record
across 2 updates, Oct 20, 2026 – Nov 13, 2026
Start date
Oct 2026→Nov 2026
Nov 13, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedDose selection utility score 3-months from last participant enrollment utilising efficacy and safety components.Time frame: 3 months from last participant enrollment → 3-4 months from last participant enrollment
Oct 20, 2026
Contact
Study contact changed: p•••@faron.com→s•••@sparkcures.com · •••2873. See the current contact
Nov 13, 2026
Show all 2 updates
  1. Nov 13, 2026
    3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • City of Hope Medical Center · Duarte, United StatesNot yet recruiting→Recruiting
    • The Christie NHS Foundation Trust · Manchester, United KingdomNot yet recruiting→Recruiting
    • Royal Cornwall Hospitals NHS Trust · Truro, United KingdomNot yet recruiting→Recruiting
    Start date Oct 2026→Nov 2026
    Contact Study contact changed: p•••@faron.com→s•••@sparkcures.com · •••2873. See the current contact
    + 1 other change: verification date
  2. Oct 20, 2026
    Not yet recruiting→Recruiting
    35 sites added — first sites in Czechia, Finland, France, Italy, Poland and 2 more
    All 7 countries

    Czechia, Finland, France, Italy, Poland, United Kingdom, United States

    Show 35 added (9 United States, 6 United Kingdom, 5 Czechia, 4 Finland, 4 France, 4 Italy, 3 Poland)
    • City of Hope Medical Center · Duarte, United States
    • University of Colorado Cancer Center · Aurora, United States
    • Yale Cancer Center · New Haven, United States
    • Moffitt Malignant Hematology & Cellular Therapy at Memorial Healthcare System · Pembroke Pines, United States
    • Mass General Brigham Cancer Institute · Boston, United States
    • University of North Carolina Lineberger Comprehensive Cancer Center · Chapel Hill, United States
    • Vanderbilt University Medical Center · Nashville, United States
    • The University of Texas MD Anderson Cancer Center · Houston, United States
    • Medical College of Wisconsin - Clinical Cancer Center - Froedtert Hospital · Milwaukee, United States
    • Fakultní nemocnice Brno · Brno, Czechia
    • Fakultní nemocnice Hradec Králové · Hradec Králové, Czechia
    • Fakultni nemocnice Ostrava · Ostrava-Poruba, Czechia
    • Ustav hematologie a krevni transfuze · Prague, Czechia
    • Vseobecna fakultni nemocnice v Praze · Prague, Czechia
    • Helsinki University Hospital Comprehensive Cancer Center · Helsinki, Finland
    • Oulu University Hospital · Oulu, Finland
    • Tampere University Hospital · Tampere, Finland
    • Turku University Hospital · Turku, Finland
    • CHU de Bordeaux · Bordeaux, France
    • Hôpital Saint-Louis · Paris, France
    • CHU de Poitiers · Poitiers, France
    • The Institut Gustave Roussy · Villejuif, France
    • AOU SS. Antonio e Biagio e Cesare Arrigo · Alessandria, Italy
    • IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, Italy
    • INOC - Istituto Nazionale Oncologico Candiolo · Candiolo, Italy
    • IRCCS Istituto Europeo di Oncologia · Milan, Italy
    • Pratia Onkologia Katowice · Katowice, Poland
    • Aidport Clinical Trials Hospital · Skórzewo, Poland
    • MTZ Clinical Research Powered by Pratia · Warsaw, Poland
    • King's College Hospital · London, United Kingdom
    • …and 5 more on the registry record
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedDose selection utility score 3-months from last participant enrollment utilising efficacy and safety components.Time frame: 3 months from last participant enrollment → 3-4 months from last participant enrollment
    + 4 other changes: verification date, registry dates, date precision and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07672769
Lead sponsor
Faron Pharmaceuticals Ltd
Responsible party
Sponsor
First posted
Jun 29, 2026
Start date
Nov 2026 (estimated)
Primary completion
Nov 2027 (estimated)
Completion
Dec 2030 (estimated)
Last update
Nov 13, 2026

Study contacts

Joab Williamson, PhD
Contact
joab.williamson@faron.com
+358 2 469 5151
SparkCures Patient Navigator
Contact
support+faron@sparkcures.com
888-676-2873
Amer M Zeidan, MBBS, MD
principal investigator · Yale University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bexmarilimab

Start the discussion